Non-steroidal anti-inflammatory drugs (NSAIDs) – exacerbated respiratory disease: epidemiology, pathogenesis, clinical findings and management
- Authors: Pavlova K.S.1, Dyneva M.E.1, Kurbacheva O.M.1
-
Affiliations:
- NRC Institute of Immunology FMBA of Russia
- Issue: Vol 17, No 3 (2020)
- Pages: 15-33
- Section: Reviews
- URL: https://journals.rcsi.science/raj/article/view/121568
- DOI: https://doi.org/10.36691/RJA1384
- ID: 121568
Cite item
Full Text
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) – exacerbated respiratory disease (N-ERD) are characterized by non-allergic hypersensitivity (intolerance) to NSAIDs and aspirin in patients with asthma and/or eosinophilic chronic rhinosinusitis with nasal polyps (CRSwNP). Asthma in N-ERD patients is usually characterized by eosinophilic inflammation, tends to become severe and intractable, and needs chronic oral corticosteroid therapy. For some patients recurrent CSwNP is more significant problem due to nasal congestion, anosmia, and multiple repeated surgeries. Intolerance to aspirin and other NSAIDs limits the choice of pain relievers and antipyretics. Accidental use of these medications can lead to dangerous consequences, including anaphylaxis. This review presents the current understanding of the N-ERD pathogenesis and perspective trends in therapy.
Full Text
##article.viewOnOriginalSite##About the authors
Ksenia S. Pavlova
NRC Institute of Immunology FMBA of Russia
Author for correspondence.
Email: ksenimedical@gmail.com
ORCID iD: 0000-0002-4164-4094
Senior Research Assistant of Bronchial Asthma, NRC Institute of Immunology FMBA of Russia, MD, PhD
Russian Federation, MoscowMiramgul E. Dyneva
NRC Institute of Immunology FMBA of Russia
Email: amanturliva.miramgul@mail.ru
ORCID iD: 0000-0003-1965-8446
post-graduate student, NRC Institute of Immunology FMBA of Russia
Russian Federation, MoscowOksana M. Kurbacheva
NRC Institute of Immunology FMBA of Russia
Email: kurbacheva@gmail.com
ORCID iD: 0000-0003-3250-0694
Head of the Asthma department, NRC Institute of Immunology FMBA of Russia, PhD, professor
Russian Federation, MoscowReferences
- Taniguchi M, Mitsui C, Hayashi H, Ono E, Kajiwara K, Mita H, et al. Aspirin-exacerbated respiratory disease (AERD): current understanding of AERD. Allergol Int. 2019;68:289–295. doi: 10.1016/j.alit.2019.05.001
- Samter M, Beers RF Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med. 1968;68(5):975–983. doi: 10.7326/0003-4819-68-5-975
- Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J. 1975;1(5949):67–69. doi: 10.1136/bmj.1.5949.67
- Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676–681. doi: 10.1016/j.jaci.2014.08.020
- Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J. 2000;16:432–436. doi: 10.1034/j.1399-3003.2000.016003432.x
- Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68(3):1219–1232. doi: 10.1111/all.12260
- Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004;328(7437):434. doi: 10.1136/bmj.328.7437.434
- Makowska JS, Burney P, Jarvis D, Keil T, Tomassen P, Bislimovska J. Respiratory hypersensitivity reactions to NSAIDs in Europe: the global allergy and asthma network (GA2LEN). Allergy. 2016;71(11):1603–1611. doi: 10.1111/all.12941
- Vally H, Taylor ML, Thompson PJ. Prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patient. Thorax. 2002;57(7):569–574. doi: 10.1136/thorax.57.7.569
- Nabavi M, Esmaeilzadeh H, Arshi S. Aspirin hypersensitivity in patients with chronic rhinosinusitis and nasal polyposis: frequency and contributing factors. Am J Rhinol Allergy. 2014;28(3):239–243. doi: 10.2500/ajra.2014.28.4034
- Tuttle KL, Schneider TR, Henrickson SE, Morris D, Abonia JP, Spergel JM. Aspirin-exacerbated respiratory disease: not always “adult-onset”. J Allergy Clin Immunol Pract. 2016;4:756–758. doi: 10.1016/j.jaip.2016.05.016
- Higashi N, Taniguchi M, Mita H, Yamaguchi H, Ono E, Akiyama K. Aspirinintolerant asthma (AIA) assessment using the urinary biomarkers, leukotriene E4 (LTE4) and prostaglandin D2 (PGD2) metabolites. Allergol Int. 2012;61:393–403. doi: 2332/allergolint.11-RA-0403
- Celik G, Paşaoğlu G, Bavbek S, Abadoğlu O, Dursun B, Mungan D. Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma. 2005;42:127–131. doi: 10.1081/jas-51326
- Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D2: a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015;135:245–252. doi: 10.1016/j.jaci.2014.07.031
- Higashi N, Mita H, Yamaguchi H, Fukutomi Y, Akiyama K, Taniguchi M. Urinary tetranor-PGDM concentrations in aspirin-intolerant asthma and anaphylaxis. J Allergy Clin Immunol. 2012;129:557e9. doi: 10.1016/j.jaci.2011.09.019
- Higashi N, Taniguchi M, Mita H, Osame M, Akiyama K. A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirinintolerant asthma. Clin Exp Allergy. 2002;32:1484e90. doi: 10.1046/j.1365-2745.2002.01507.x
- Buchheit KM, Cahill KN, Katz HR, Murphy KC, Feng C, Lee-Sarwar K, et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137:1566e76. doi: 10.1016/j.jaci.2015.10.020
- Pleskow WW, Stevenson DD, Mathison DA, Simon RA, Schatz M, Zeiger RS. Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol. 1982;69:11e9. doi: 10.1016/0091-6749(82)90081-1
- Sanak M, Gielicz A, Bochenek G, Kaszuba M, Nizankowska-Mogilnicka E, Szczeklik A. Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype. J Allergy Clin Immunol. 2011;127:1141–1147. doi: 10.1016/j.jaci.2010.12.1108
- Yamaguchi H, Higashi N, Mita H, Ono E, Komase Y, Nakagawa T, et al. Urinary concentrations of 15-epimer of lipoxin A4 are lower in patients with aspirin-intolerant compared with aspirin-tolerant asthma. Clin Exp Allergy. 2011;41(12):1711–1718. doi: 10.1111/j.1365-2222.2011.03839.x
- Picado C, Fernandez-Morata JC, Juan M, Roca-Ferrer J, Fuentes M, Xaubet A, Mullol J. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med. 1999;162:291–296. doi: 10.1164/ajrccm.160.1.9808048
- Cahill KN, Raby BA, Zhou X, Guo F, Thibault D, Baccarelli A, et al. Impaired E prostanoid 2 expression and resistance to prostaglandin E2 in nasal polyp fibroblasts from subjects with aspirin-exacerbated respiratory disease. Am J Respir Cell Mol Biol. 2016;54:34–40. doi: 10.1165/rcmb.2014-0486OC
- Laidlaw TM, Kidder MS, Bhattacharyya N, Xing W, Shen S, Milne GL, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood. 2012;119:3790e8. doi: 10.1182/blood-2011-10-384826
- Mitsui C, Kajiwara K, Hayashi H, Ito J, Mita H, Ono E, et al. Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137:400e11. doi: 10.1016/j.jaci.2015.05.041
- Artis D, Spits H. The biology of innate lymphoid cells. Nature. 2015;517:293–301. doi: 10.1038/nature14189
- Doherty TA, Broid DH. Lipid regulation of group 2 innate lymphoid cell function: Moving beyond epithelial cytokines. J Allergy Clin Immunol. 2018;141:1587–1589. doi: 10.1016/j.jaci.2018.02.034
- Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45–56. doi: 10.1038/ni.3049
- Locksley RM. Asthma and allergic inflammation. Cell. 2010;140(6):777–783. doi: 10.1016/j.cell.2010.03.004
- Hams E, Bermingham ER, Fallon PG. Macrophage and innate lymphoid cell interplay in the genesis of fibrosis. Front Immunol. 2015;6:597. doi: 10.3389/fimmu.2015.00597
- Tashireva LA, Zavgorodskaya KO, Perelmuter VM. Role of innate lymphoid cells during cancer. Cytology. 2016;58(12):901–907 (In Russ.).
- Liu T, De Los Santos FG, Ding L, Wu Z, Phan SH. Amphiregulin promotes fibroblast activation in pulmonary fibrosis. FASEB J. 2016;30(S1):50.6–50.6. doi: 10.1096/fasebj.30.1_supplement.50.6
- Buhl R, Humbert M, Bjermer L, Chanez P, Heaney LG, Pavord I, et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J. 2017;49(5):1700634. doi: 10.1183/13993003.00634-2017
- Von Moltke J, O’Leary CE, Barrett NA, Kanaoka Y, Frank Austen K, Locksley RM. Leukotrienes provide an NFAT-dependent signal that synergizes with IL-33 to activate ILC2s. J Exp. 2017;214(1):27–37. doi: 10.1084/jem.20161274
- Allakhverdi Z, Comeau MR, Jessup HK. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med. 2007;204:253–258. doi: 10.1084/jem.20062211
- Zhou W, Toki S, Zhang J, Goleniewksa K, Newcomb DC, Cephus JY, et al. Prostaglandin I2 signaling and inhibition of group 2 innate lymphoid cell responses. Am J Respir Crit Care Med. 2016;193:31–42. doi: 10.1164/rccm.201410-1793OC
- Kloze CS, Artis D. Innate lymphoid cells control signaling circuits to regulate tissue-specific immunity. Cell Research. 2020;30:475–491. doi: 10.1038/s41422-020-0323-8
- Imai Y, Yasuda K, Sakaguchi Y, Haneda T, Mizutani H, Yoshimoto T, et al. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci USA. 2013;110:13921–13926. doi: 10.1073/pnas.1307321110
- Almeida I, Silva SV, Fonseca AR, Silva I, Vasconcelos C, Lima M. T and NK cell phenotypic abnormalities in systemic sclerosis: a cohort study and a comprehensive literature review. Clin Rev Allergy Immunol. 2015;49:347–369. doi: 1007/s12016-015-8505-8
- Melhem A, Muhanna N, Bishara A, Alvarez CE, Ilan Y, Bishara T, et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol. 2006;45:60–71. doi: 10.1016/j.jhep.2005.12.025
- Amelink M, de Groot JC, de Nijs SB, Lutter R, Zwinderman AH, Peter JS, et al. Severe adult-onset asthma: a distinct phenotype. J Allergy Clin Immunol. 2013;132:336–341. doi: 10.1016/j.jaci.2013.04.052
- Lemiere C, Ernst P, Olivenstein R, Yamauchi Y, Govindaraju K, Ludwig MS, et al. Airway inflammation assessed by invasive and noninvasive means in severe asthma: eosinophilic and noneosinophilic phenotypes. J Allergy Clin Immunol. 2006;118:1033–1039. doi: 10.1016/j.jaci.2006.08.003
- Ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med. 2001;164:744–748. doi: 10.1164/ajrccm.164.5.2011026
- Tran TN, Khatry DB, Ke X, Ward CK, Gossage D. High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. Ann Allergy Asthma Immunol. 2014;113:19–24. doi: 10.1016/j.anai.2014.04.011
- Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L; TENOR Study Group. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2005;116:970–975. doi: 10.1016/j.jaci.2005.08.035
- Abraham B, Barreiro E, Anto JM, Bel EH. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003;22:470–477. doi: 10.1183/09031936.03.00261903
- Plaza V, Serrano J, Picado C, Sanchis J. Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma. Eur Respir J. 2002;19(5):846–852. doi: 10.1183/09031936.02.00241502
- Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, et al. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy. 2012;67:91–98. doi: 10.1111/j.1398-9995.2011.02709.x
- Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol. 2003;111:913–921. doi: 10.1067/mai.2003.1487
- Hamilos DL, Leung DY, Wood R, Cunningham L, Bean DK, Yasruel Z, et al. Evidence for distinct cytokine expression in allergic versus nonallergic chronic sinusitis. J Allergy Clin Immunol. 1995;96:537–544. doi: 10.1016/s0091-6749(95)70298-9
- Toros SZ, Bolukbasi S, Naiboglu B, Er B, Akkaynak C, Noshari H, Egeli E. Comparative outcomes of endoscopic sinus surgery in patients with chronic sinusitis and nasal polyps. Eur Arch Otorhinolaryngol. 2007;264:1003–1008. doi: 10.1007/s00405-007-0301-5
- Banerji A, Piccirillo JF, Thawley SE, Levitt RG, Schechtman KB, Kramper MA, et al. Chronic rhinosinusitis patients with polyps or polypoid mucosa have a greater burden of illness. Am J Rhinol. 2007;21:19–26. doi: 10.2500/ajr.2007.21.2979
- Poetker DM, Mendolia-Loffredo S, Smith TL. Outcomes of endoscopic sinus surgery for chronic rhinosinusitis associated with sinonasal polyposis. Am J Rhinol. 2007;21:84–88. doi: 10.2500/ajr.2007.21.2978
- Serrano E, Neukirch F, Pribil C, Jankowski R, Klossek JM, Chanal I, El Hasnaoui A. Nasal polyposis in France: impact on sleep and quality of life. J Laryngol Otol. 2005;119(7):543–549. doi: 10.1258/0022215054352108
- Chung JH, Lee YJ, Kang TW, Kim KR, Jang DP, In Kim Y, Cho SH. Altered quality of life and psychological health (SCL-90-R) in patients with chronic rhinosinusitis with nasal polyps. Ann Otol Rhinol Laryngol. 2015;124(8):663–670. doi: 10.1177/0003489415576181
- Hope AP, Woessner KA, Simon RA, Stevenson DD. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2009;123:406–410. doi: 10.1016/j.jaci.2008.09.048
- O’Sullivan S, Dahlen B, Dahlen SE, Kumlin M. Increased urinary excretion of the prostaglandin D2 metabolite 9 alpha, 11 beta-prostaglandin F2 after aspirin challenge support mast cell activation in aspirin-induced airway obstruction. J Allergy Clin Immunol. 1996;98:421–432. doi: 10.1016/s0091-6749(96)70167-7
- Bavbek S, Celik G, Demirel YS, Misirligil Z. Risk factors associated with hospitalizations for asthma attacks in Turkey. Allergy Asthma Proc. 2003;24:437–442.
- Kowalski LM, Agache I, Bavbek S, Bakirtas A, Blanca M, Bochenek G, et al. Diagnosis and Management of NSAID-Exacerbated Respiratory Disease (N-ERD) – a EAACI position paper. Allergy. 2019;74(1):28–39. doi: 10.1111/all.13599
- Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) – classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy. 2011;66:818–829. doi: 10.1111/j.1398-9995.2011.02557.x
- Rossiiskoe respiratornoe obshchestvo. Rossiiskaya Assotsiatsiya Allergologov i Klinicheskikh Immunologov. Soyuz pediatrov Rossii. Federal’nye klinicheskie rekomendatsii po diagnostike i lecheniyu bronhial’noi astmy. 2019 [cited 2020 Aug 15]. Available from: https://raaci.ru/education/clinic_recomendations.html (In Russ.).
- Obase Y, Shimoda T, Tomari SY, Mitsuta K, Kawano T, Matsuse H, Kohno S. Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients. Chest. 2002;121:143–150. doi: 10.1378/chest.121.1.143
- Berges-Gimeno MP, Simon RA, Stevenson DD. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy. 2002;32:1491–1496. doi: 10.1046/j.1365-2745.2002.01501.x
- Soler ZM, Mace JC, Litvack JR, Smith TL. Chronic rhinosinusitis, race, and ethnicity. Am J Rhinol Allergy. 2012;26:110–116. doi: 10.2500/ajra.2012.26.3741
- Hamilos DL. Chronic rhinosinusitis: Epidemiology and medical management. J Allergy Clin Immunol. 2011;128(4):693–707. doi: 10.1016/j.jaci.2011.08.004
- Khalmuratova R, Park JW, Shin HW. Immune cell responses and mucosal barrier disruptions in chronic rhinosinusitis. Immune Netw. 2017;17:60. doi: 10.4110/in.2017.17.1.60
- Mullol J, Picado C. Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2013;33:163–176. doi: 10.1016/j.iac.2012.11.002
- Stevenson DD, Simon RA, Mathison DA. Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges. J Allergy Clin Immunol. 1980;66:82–88. doi: 10.1016/0091-6749(80)90143-8
- White AA, Stevenson DD. Aspirin desensitization in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2013;33:211–222. doi: 10.1016/j.iac.2012.10.013
- Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med. 2006;354:2689–2695. doi: 10.1056/NEJMct055184
- Djukanovic R, Wilson SJ, Kraft M. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170(6):583–593. doi: 10.1164/rccm.200312-1651OC
- Busse W, Corren J, Lanier BQ. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184–190. doi: 10.1067/mai.2001.117880
- Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011;139:28–35. doi: 10.1378/chest.10-1194
- Deschildre A, Marguet C, Salleron J. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J. 2013;42:1224–1233. doi: 10.1183/09031936.00149812
- Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: the ‘realworld’ effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107:1141–1151. doi: 10.1016/j.rmed.2013.04.017
- Tajiri T, Matsumoto H, Hiraumi H, Ikeda H, Morita K, Izuhara K, et al. Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma. Ann Allergy Asthma Immunol. 2013;110(5):386–393. doi: 10.1016/j.anai.2013.01.024
- Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110–116. doi: 10.1016/j.jaci.2012.07.047
- Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985–993. doi: 10.1056/NEJMoa0805435
- Shrimanker R, Keene O, Hynes G, Wenzel S, Yancey S, Pavord ID. Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis. Am J Respir Crit Care Med. 2019;200(10):1308–1312. doi: 10.1164/rccm.201903-0599LE
- Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198–1207. doi: 10.1056/NEJMoa1403290
- Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–1197. doi: 10.1056/NEJMoa1403291
- Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016;38(9):2058–2070.e1. doi: 10.1016/j.clinthera.2016.07.010
- Khurana S, Brusselle GG, Bel EH, FitzGerald JM, Masoli M, Korn S, et al. Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX Study. Clin Ther. 2019;41(10):2041–2056. doi: 10.1016/j.clinthera.2019.07.007
- Albers FC, Licskai C, Chanez P, Bratton DJ, Bradford ES, Yancey SW, et al. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma. Respir Med. 2019;159:105806. doi: 10.1016/j.rmed.2019.105806
- Albers FC, Papi A, Taillé C. Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA. Respir Res. 2019;20(1):169. doi: 10.1186/s12931-019-1134-7
- Chapman KR, Albers FC, Chipps B, Muñoz X, Devouassoux G, Bergna M, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019;74(9):1716–1726. doi: 10.1111/all.13850
- Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989–995. doi: 10.1016/j.jaci.2011.07.056
- Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebocontrolled study. Am J Respir Crit Care Med. 2011;184(10):1125–1132. doi: 10.1164/rccm.201103-0396OC
- Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. doi: 10.1016/S2213-2600(15)00042-9
- Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 Study of Reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799–810. doi: 10.1016/j.chest.2016.03.018
- Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789–798. doi: 10.1016/j.chest.2016.03.032
- Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–2127. doi: 10.1016/S0140-6736(16)31324-1
- FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–2141. doi: 10.1016/S0140-6736(16)31322-8
- Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486–2496. doi: 10.1056/NEJMoa1804092
- Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;1–13. doi: 10.1016/S0140-6736(19)31881-1